Loss of exclusivityDecember 2035latest FDA-listed patent expiry
CompanyPolarean, Inc. →See this company's full patent-cliff portfolio
Drug detail
Brand name
XENOVIEW
Active ingredient
XENON XE-129 HYPERPOLARIZED
Strength
N/A
Dosage form
GAS
Route
INHALATION
Modality
Small molecule
FDA approval
December 2022
Marketing status
RX
Listed patents
Patent
Expires
Type
11052161
December 2035
product
10583205
February 2035
product
Regulatory exclusivity
Code
Expires
NCE
December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.